Trial Activity Trends
Data updated: Jun 28, 2026
Comparing 2024-2025 vs 2020-2021 trial starts by indication
Rising Indications
+30% or more trial activity growth
Lupus Nephritis Immunology
'20
'21
'22
'23
'24
'25
'26
+320%
10→42
Lupus Immunology
'20
'21
'22
'23
'24
'25
'26
+243%
46→158
Liver Failure Hepatology
'20
'21
'22
'23
'24
'25
'26
+240%
5→17
Obesity Metabolic
'20
'21
'22
'23
'24
'25
'26
+227%
151→494
Myasthenia Gravis Immunology
'20
'21
'22
'23
'24
'25
'26
+216%
19→60
Arrhythmia Cardiovascular
'20
'21
'22
'23
'24
'25
'26
+200%
6→18
Stroke Cardiovascular
'20
'21
'22
'23
'24
'25
'26
+189%
94→272
NMOSD Immunology
'20
'21
'22
'23
'24
'25
'26
+183%
6→17
Immune Thrombocytopenia Rare Disease
'20
'21
'22
'23
'24
'25
'26
+169%
36→97
IgA Nephropathy Immunology
'20
'21
'22
'23
'24
'25
'26
+161%
18→47
Vitiligo Dermatology
'20
'21
'22
'23
'24
'25
'26
+142%
12→29
Bipolar Disorder CNS
'20
'21
'22
'23
'24
'25
'26
+133%
15→35
IBD Immunology
'20
'21
'22
'23
'24
'25
'26
+133%
6→14
Constipation Gastrointestinal
'20
'21
'22
'23
'24
'25
'26
+127%
11→25
Hypertrophic Cardiomyopathy Cardiovascular
'20
'21
'22
'23
'24
'25
'26
+114%
7→15
Stable Indications
-30% to +30% change
Solid Tumor (Advanced) Oncology
'20
'21
'22
'23
'24
'25
'26
+23%
1646→2017
Non-Hodgkin Lymphoma Oncology
'20
'21
'22
'23
'24
'25
'26
+15%
994→1141
Breast Cancer Oncology
'20
'21
'22
'23
'24
'25
'26
-1%
894→882
Prostate Cancer Oncology
'20
'21
'22
'23
'24
'25
'26
+8%
422→456
Lung Cancer (General) Oncology
'20
'21
'22
'23
'24
'25
'26
-30%
404→284
Multiple Myeloma Oncology
'20
'21
'22
'23
'24
'25
'26
+8%
245→264
Sarcoma Oncology
'20
'21
'22
'23
'24
'25
'26
-13%
293→255
Ovarian Cancer Oncology
'20
'21
'22
'23
'24
'25
'26
+27%
241→306
Hematologic Malignancies Oncology
'20
'21
'22
'23
'24
'25
'26
+6%
248→264
Bladder Cancer Oncology
'20
'21
'22
'23
'24
'25
'26
0%
250→249
Declining Indications
-30% or more trial activity decline
COVID-19 Infectious Disease
'20
'21
'22
'23
'24
'25
'26
-91%
1967→178
Hepatitis C Infectious Disease
'20
'21
'22
'23
'24
'25
'26
-71%
24→7
Pneumonia Respiratory
'20
'21
'22
'23
'24
'25
'26
-64%
165→60
Muscle Spasm Musculoskeletal
'20
'21
'22
'23
'24
'25
'26
-50%
8→4
Fabry Disease Rare Disease
'20
'21
'22
'23
'24
'25
'26
-50%
6→3
Myelofibrosis Oncology
'20
'21
'22
'23
'24
'25
'26
-39%
80→49
Melanoma Oncology
'20
'21
'22
'23
'24
'25
'26
-36%
393→253
Merkel Cell Carcinoma Oncology
'20
'21
'22
'23
'24
'25
'26
-35%
31→20
NASH/NAFLD Metabolic
'20
'21
'22
'23
'24
'25
'26
-35%
115→75
Opioid Use Disorder CNS
'20
'21
'22
'23
'24
'25
'26
-31%
103→71
Showing top 10 rising and declining trends
Upgrade to Pro for full trend analysis and export capabilities
See Pro FeaturesMethodology: Compares average trial starts in 2024-2025 vs 2020-2021.
Sparklines: Show trial volume 2020→2026 (left to right).